Journal Article

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial

Erasmus, Mzwandile, Plaatjie, Patiswa, Leukes, Daphne, Van As, Danelle, Solomoms, Roxanne, Cloete, Yolundi, Kola–Cassiem, Fazlin, Scriba, Thomas J, Vazana, Bongiwe, Keyser, Alana, Baartman, Veronica, Jansen, Ruwijda, Nkantsu, Lungisa, Nqweniso, Sizwe, Abrahams, Charmaine, Mtshamba, Eunice, Veldsman, Ashley, Abrahams, Deborah, Du Preez, Karen, Kruger, Sandra, Mulenga, Humphrey, Tameris, Michele, Walzl, Gerhard, Maart, Theresa, Hesseling, Anneke C, Hatherill, Mark, Xoyana, Noncedo, Francis, Claudia, Noble, Julia, Africa, Hadn, Goedeman, Katriena, Khomba, Gloria, McShane, Helen, Bilek, Nicole, Petersen, Christel, van Ster, Daphne, Bavuma, Beauty, Hopley, Christiaan, Mvinjelwa, Boniswa, Damons, Margareth, Mouton, Angelique Hendricks, Nemes, Elisa, Makhethe, Lebohang, van der Zalm, Marieke, Louw, Loyiso, Opperman, Fajwa, Luabeya, Angelique, Rossouw, Susan, De Vos, Ronel, van Rooyen, Elma, Jones, Carolynne, Swanepoel, Liticia, Botes, Natasja, Rose, Penelope, Geldenhuys, Mandy, Dlakavu, Portia, Hanekom, Willem A, Mbaba, Sharon, Golliath, Sandra, Mauff, Katya, van Deventer, Heidi, Mbabwe, Simbarashe, Kagina, Benjam

2018

Overview

Vaccination of human immunodeficiency virus (HIV)-infected infants with bacille Calmette-Guérin (BCG) is contraindicated. HIV-exposed newborns need a new tuberculosis vaccination strategy that protects against tuberculosis early in life and avoids the potential risk of BCG disease until after HIV infection has been excluded. This double-blind, randomized, controlled trial compared newborn MVA85A prime vaccination (1 × 108 PFU) vs Candin® control, followed by selective, deferred BCG vaccination at age 8 weeks for HIV-uninfected infants and 12 months follow-up for safety and immunogenicity. A total of 248 HIV-exposed infants were enrolled. More frequent mild-moderate reactogenicity events were seen after newborn MVA85A vaccination. However, no significant difference was observed in the rate of severe or serious adverse events, HIV acquisition (n = 1 per arm), or incident tuberculosis disease (n = 5 MVA85A; n = 3 control) compared to the control arm. MVA85A vaccination induced modest but significantly higher Ag85A-specific interferon gamma (IFNγ)+ CD4+ T cells compared to control at weeks 4 and 8 (P < .0001). BCG did not further boost this response in MVA85A vaccinees. The BCG-induced Ag85A-specific IFNγ+ CD4+ T-cell response at weeks 16 and 52 was of similar magnitude in the control arm compared to the MVA85A arm at all time points. Proliferative capacity, functional profiles, and memory phenotype of BCG-specific CD4 responses were similar across study arms. MVA85A prime vaccination of HIV-exposed newborns was safe and induced an early modest antigen-specific immune response that did not interfere with, or enhance, immunogenicity of subsequent BCG vaccination. New protein-subunit and viral-vectored tuberculosis vaccine candidates should be tested in HIV-exposed newborns. NCT01650389.

• Publisher: Oxford University Press
• Subject: Adult / and Commentaries / Anti-Retroviral Agents - therapeutic use / Antigens / Antigens, Bacterial - immunology / Bacillus Calmette-Guerin vaccine / BCG / BCG Vaccine - adverse effects / BCG Vaccine - therapeutic use / CD4 antigen / CD4 Lymphocyte Count / CD4-Positive T-Lymphocytes - immunology / Control methods / Disease control / Double-Blind Method / Exposure / Female / HIV / HIV Infections - drug therapy / HIV Infections - immunology / Human immunodeficiency virus / Humans / Immune response / Immune system / Immunization / Immunogenicity / Immunogenicity, Vaccine / Infant / Infant, Newborn / Infants / Interferon / Interferon-gamma - immunology / Lymphocytes / Lymphocytes T / Male / Mothers / Mycobacterium tuberculosis / Neonates / Newborn babies / Phenotypes / Public health / Randomization / Safety / Tuberculin Test / Tuberculosis / Tuberculosis - prevention & control / Tuberculosis Vaccines - adverse effects / Tuberculosis Vaccines - therapeutic use / Vaccination / Vaccines / Vaccines, DNA / Viruses / γ-Interferon